WebApr 13, 2024 · Gene scissors find target for testicular cancer therapy Bonn researchers uncover contribution of protein degradation processes to cisplatin resistance in germ cell tumors: Cisplatin is used successfully in the chemotherapy of testicular cancer. WebDec 9, 2024 · Ovarian cancer (OC) is the 11th most common cancer in women and the fifth leading cause of cancer-related death in the world, 1 with an estimation of 314,000 newly diagnosed cases and ...
Concomitant radiation therapy and targeted cisplatin …
WebApr 13, 2024 · Researchers at the University Hospital Bonn (UKB) have now been able to elucidate a mechanism underlying cisplatin resistance in testicular cancer. Using CRISPR … WebJan 27, 2024 · Patients with locally advanced disease also elicited a better median OS with the triplet (n = 77) at 19.2 months compared with 13.7 months with the doublet (n = 41). Further, the median PFS was 9.3 months with the addition of nab-paclitaxel vs 7.6 months with gemcitabine and cisplatin alone. “At the end of the day, this study did not meet its ... psychotherapie apeldoorn
Advanced cisplatin nanoformulations as targeted drug
WebSep 24, 2024 · Cisplatin (CDDP) is the drug of choice against different types of cancer. However, tumor cells can acquire resistance to the damage caused by cisplatin, generating genetic and epigenetic changes that lead to the generation of resistance and the activation of intrinsic resistance mechanisms in cancer cells. Among them, we can find mutations, … WebTargeted nanomedicine shows great promise in delivering cisplatin for maximizing efficacy while minimizing off-target toxicity. This article surveyed the recent progress and challenges of targeted nanomedicine in managing resistance and toxicity of cisplatin in both fundamental and clinical aspects. Particularly, we focused on three major ... WebThe structure of the [Pd 2 L 4 ⊃(cisplatin) 2](BF 4) 4 host–guest adduct has been confirmed by 1 H NMR spectroscopy, HR-ESMS and X-ray crystallography. Additionally we have demonstrated that the cage–cisplatin host–guest adduct can be quantatively disassembled upon the addition of a competing ligand , releasing the cisplatin guest. hot air up or down